Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses

Keyphrases

• Dendritic Cells 100%
• In Vivo Antitumor Activity 100%
• Lysate 100%
• Surface Antigen 100%
• Protective Response 100%
• DC Vaccine 100%
• Tumor Cells 75%
• CPG 7909 75%
• Tumor 50%
• Syngeneic 50%
• Antitumor 50%
• Protective Effect 25%
• Intravenous Administration 25%
• Cytotoxic T Lymphocytes 25%
• Vaccine Strategy 25%
• CpG ODN 25%
• Unvaccinated 25%
• Improved Survival 25%
• Splenocytes 25%
• Precursor Cells 25%
• Day 14 25%
• Tumor Challenge 25%
• Splenic Tumor 25%
• Co-injection 25%
• Mean Frequency 25%
• Adjuvant Effect 25%

Medicine and Dentistry

• Acute Myelogenous Leukemia 100%
• Neoplasm 100%
• Cell Antigen 100%
• Dendritic Cell 100%
• Tumor Cell 75%
• Agatolimod 75%
• In Vitro 25%
• Precursor 25%
• Cytotoxic T-Cell 25%
• Adjuvant Therapy 25%
• CpG Oligodeoxynucleotide 25%

Immunology and Microbiology

• Dendritic Cell 100%
• Cell Lysate 100%
• Cell Antigen 100%
• Tumor Cell 75%
• Agatolimod 75%
• Syngenic 50%
• Cytotoxic T Cell 25%
• Splenocyte 25%
• Precursor 25%
• CpG Oligodeoxynucleotide 25%